STOCK TITAN
  1. Home
  2. Sec-filings
  3. ESPR
  4. [144] Esperion Therapeutics, Inc. SEC Filing

[144] Esperion Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock ESPR logo
Esperion Therape

NASDAQ:ESPR

ESPR Rankings

#4950 Ranked by Market Cap
N/A Ranked by Dividends

ESPR Latest News

Jul 8, 2025
Esperion Reaches Settlement Agreement with Third ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040
Jul 1, 2025
Esperion Appoints Craig Thompson to Board of Directors
Jun 2, 2025
Esperion Reaches Settlement Agreement with Second ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040
May 20, 2025
Esperion to Participate in Upcoming June Investor Conferences
May 12, 2025
Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040

ESPR Latest SEC Filings

Jul 18, 2025
[Form 4] Esperion Therapeutics, Inc. Insider Trading Activity
Jul 17, 2025
[144] Esperion Therapeutics, Inc. SEC Filing
Jul 2, 2025
[Form 4] Esperion Therapeutics, Inc. Insider Trading Activity
Jul 2, 2025
[Form 3] Esperion Therapeutics, Inc. Initial Statement of Beneficial Ownership
Jul 1, 2025
[8-K] Esperion Therapeutics, Inc. Reports Material Event

ESPR Stock Data

245.77M
197.10M
1%
65.72%
14.73%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
ANN ARBOR